

## RELEVANT SCIENTIFIC LITERATURE

### Effects of Poloxamer-188 on Heart Structure and Function.

Egan, J.R., Baines, D. Street, N., et al., (2009). Myocardial membrane injury in pediatric cardiac surgery: an animal model. *J. Thorac. Cardiovasc. Surg.* **137**: 1154-1162.

Ilisar, I., Wang, M., Jiang, A., Dye, K., Markham, B., Sabbah, H.N. (2010) Acute intravenous bolus injection of Poloxamer-188 improves left ventricular function in dogs with heart failure *J. Am. Col. Cardiol.* **55** (Suppl. 1): A16.E146.

Spurney, C.F., Guerron, A.D., Yu, Q., Sali, A., van der Meulen, J.H., Hoffman, E.P., and Nagaraju, K. (2011). Membrane sealant poloxamer-188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. *BMC Cardiovasc. Disorders* **11**:20 doi:10.1186/1471-2261-11-20.

Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, Kornegay JN, Metzger JM. (2010). Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. *J Clin Invest.* Mar 15. pii: 41329. doi: 10.1172/JCI41329.

Watanabe, M., and Okada, T. (2003). Lysophosphatidylcholine –induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart. *Mol. Cell. Biochem.* **248**: 209-215.

Yasuda, S., Townsend, D., Michele, D.E., Farve, E.G., Day, S.M. and Metzger, J. (2005). Dystrophic heart failure blocked by membrane sealant poloxamer. *Nature* **436**: 1025-1029.

### Poloxamer-188 Effects on Skeletal Muscle.

Collins, J.M., Despa, F., and Lee RC. (2007). Structural and functional recovery of electroporabilized skeletal muscle in-vivo after treatment with surfactant poloxamer 188. *Biochim Biophys Acta.* **1768**:1238-46.

Murphy, A.D., McCormack, A.C., Bichara, D.A., Nguyen, J.T., Randolph, M.A., Watkins, M.T., Lee, R.C., and Austen, W.G. 2010. Poloxamer 188 protects against ischemia-reperfusion injury in a murine hind-limb model. *Plast. Reconstr. Surg.* **125**: 1651-1660.

Ng, R., Metzger, J.M., Clafin, D.R., and Faulkner. J.A. (2008). Poloxamer 188 reduces the contraction-induced force decline in lumbrical muscles from mdx mice. *Am. J. Physiol. Cell Physiol.* **295**: C146-150.

### **Membrane Repair Effects of Poloxamer.**

Agarwal, J., Walsh, A., and Lee, R.C. (2005). Multimodal strategies for resuscitating injured cells. *Ann. N.Y. Acad. Sci.* **1066**: 295-309.

Greenebaum, B., Blossfield, K., Hannig, J., Carrillo, C.S., Beckett, M.A., Weichselbaum, R.R., Lee, R.C. (2004). Poloxamer 188 prevents acute necrosis of adult skeletal muscle cells following high-dose irradiation. *Burns*. **30**: 539-547.

Lee, R.C., River, L.P., Pan, F.S., Ji, L., and Wolmann, R.L. (1992). Surfactant-induced sealing of electroporabilized skeletal muscle membranes in vivo. *Proc. Natl. Acad. Sci. USA*, **89**: 4524-4528.

Maskarinec, S.A., Wu, G., and Lee, K.Y.C. (2005) Membrane sealing by polymers. *Ann. N.Y. Acad. Sci.* **1066**: 310-320.

Matthews, K.L. 2nd, Aarsvold, J.N., Mintzer, R.A., Chen, C.T., and Lee, R.C. (2006). Tc-99m pyrophosphate imaging of poloxamer-treated electroporated skeletal muscle in an in vivo rat model. *Burns* **32**: 755-64.

McNeil, P.L., and Steinhardt, R.A. (2003). Plasma membrane disruption: repair, prevention, adaptation. *Annu. Rev. Cell Dev. Biol.* **19**: 697-731.

Merchant, F.A., Holmes, W.H., Capelli-Schellpfeffer, M., Lee, R.C., and Toner, M. (1998). Poloxamer 188 enhances functional recovery of lethally heat-shocked fibroblasts. *J. Surg. Res.* **74**:131-140.

Serbest, G., Horwitz, J., and Barbee, K. (2005) The effect of poloxamer-188 on neuronal cell recovery from mechanical injury. *J. Neurotrauma* **22**: 119-132.

Steinhardt, R.A. (2005). The mechanisms of cell membrane repair. A tutorial guide to key experiments. *Ann. N.Y. Acad. Sci.* **1066**:152-165.

Terry, M.A., Hannig, J., Carrillo, C.S., Beckett, M.A., Weichselbaum, R.R. and Lee, R.C. (2005). Oxidative cell membrane alteration. Evidence for surfactant-mediated sealing. *Ann. N.Y. Acad. Sci.* **1066**: 274-284.

Togo, T., Alderton, J.M., Bi, G.-Q., and Steinhardt, R.A. (1999). The mechanism of facilitated cell membrane resealing. *J. Cell Sci.* **112**: 719-731.



### **Clinical Experience with Poloxamer-188.**

Adams-Graves, P., Kedar, A., Koshy, M., Steinberg, M., Veith, R., Ward, D., Crawford, R., Edwards, S., Bustrack, J., and Emanuele, M. (1997). RheothRx (Poloxamer-188) injection for the acute painful episode of sickle cell disease: a pilot study. *Blood* **90**: 2041-2046.

Collaborative Organization for RheothRx Evaluation (Core) (1997). Effects of RheothRx on mortality, morbidity, left ventricular function and infarct size in patients with acute myocardial infarction. *Circulation* **96**: 192-201.

Emanuele, R.M. (1998). FLOCOR: a new anti-adhesive, rheologic agent. *Exp. Opin. Invest. Drugs* **7**: 1193-1200.

Gibbs, W.J., and Hagemann, T.M. (2004) Purified poloxamer 188 for sickle cell vaso-occlusive crisis. *Ann. Pharmacother.* **38**: 320-324.

Orringer, E.P., Casella, J.F., Ataga, K.I., Koshy, M., Adams-Graves, P., Luchtman-Jones, L., Wun, T., Watanabe, M., Shafer, F., Kutlar, A., Abboud, M., Steinberg, M., Adler, B., Swerdlow, P., Terregino, C., Saccente, S., Files, B., Ballas, S., Brown, R., Wojtowicz-Praga, S., Grindel, J.M. (2001). Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. *JAMA.* **286**: 2099-2106.

O'Keefe, J.H., Grines, C.L., DeWood, M.A., Schaer, G.L., Browne, K., Magorien, R.D., et al. (1996). Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am. J. Cardiol.* **78**: 747-750.

Maynard, C., Swenson, R., Paris, J.A., Martin, J.S., Hallstrom, A.P., Cerqueira, M.D., and Weaver, W.D. (1998). Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. *Am. Heart J.* **135**: 797-804.

Schaer, G.L., Spaccavento, L.J., Browne, K.F., Krueger, K.A., Krichbaum, D., Phelan, J.M., Fletcher, W.O., Grines, C.L., Edwards, S., Jolly, M.K., and Gibbons, R.J. (1996) Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. *Circulation* **94**: 298-307.

Toth, K., Bogar, L., Juricskay, I., Keltai, M., Yusuf, S., Haywood, L.J., Meiselman, H.J. (1997). The Effect of RheothRx Injection on the Hemorheological Parameters in Patients with Acute Myocardial Infarction. *Clin Hemorheol Microcirc* **17**: 117-125.



### **ADME of Poloxamer-188.**

Grindel, J.M., Jaworski, T., Piraner, O., Emanuele, R.M., and Balasubramanian, M. (2002a). Distribution, metabolism and excretion of a novel surface-active agent, purified Poloxamer 188 in rats dogs and humans. *J. Pharm. Sci.* **91**: 1936-1947.

Grindel, J.M., Jaworski, T., Emanuele, R.M., and Culbreth, P. (2002b). Pharmacokinetics of a novel surface-active agent, purified Poloxamer188 in rat, rabbit, dog and man. *Biopharm. Drug Dispos.* **23**: 87-103.

Jewell, R.C., Khor, D.F., Kisor, D.F., LaCroix, K.A.K., and Wargin, W.A. (1997) Pharmacokinetics of RheothRx Injection in Healthy Male Volunteers. *J. Pharm. Sci.* **86**: 808-812.

Quezada, A., Larson, J., French, M., Ponce, R., Perrard, J., Durland, R., and Coleman, M. (2004). Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models. *J. Pharmacy Pharmacol.* **56**: 177-185.

Wang, Z. Y., and I. J. Stern. 1975. Disposition in rats of a polyoxypropylenepolyoxyethylene copolymer used in plasma fractionation. *Drug Metab. Dispos.* **3**: 536-542.

Willcox, M.L., Newman, M.M., and Paton, B.C. (1978). A study of labeled pluronic F-68 after intravenous injection into the dog. *J. Surg. Res.* **25**: 349-356.

### **Poloxamer-188 Safety Studies.**

Ballas, S.K., Files, B., Luchtman-Jones, L., Benjamin, L., Swerdlow, P., Hilliard, L., Coates, T., Abboud, M., Wojtowicz-Praga, S., and Grindel, J.M. (2004). Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. *Hemoglobin* **28**: 85-102.

Duvinage C, Millecamps S, Sagnier A, Guffroy M, Sarsat J.-P, Belin V.(1996). One-month intravenous toxicity studies of poloxamer 188 in male Sprague-Dawley rats and in beagle dogs. *Toxicology Letters* **88** (Supplement 1): 101.

Jewell, R.C., Khor, D.F., Kisor, D.F., LaCroix, K.A.K., and Wargin, W.A. (1997) Pharmacokinetics of RheothRx Injection in Healthy Male Volunteers. *J. Pharm. Sci.* **86**: 808-812.

Leaf, C.W. (1967). Toxicology of some nonionic surfactants. *Soap & Chem. Specialties.* **43**: 48-51 and 106-110.

Magnusson, G., Olsson, T., Nyberg, J.-A. (1986). Toxicity of Pluronic F-68. *Tox. Lett.* **30**: 203-207.

Modi, N.B. (1999). Flocor CytRx Corp. *IDrugs* **2**: 366-374.

Rodriguez, S.C. and Singer, E.J. (1996). Toxicology of polyoxyalkylene block copolymers. *In Non-Ionic Surfactants: Polyoxyalkylene Block Copolymers*, Nace VM (ed). Marcel Dekker: New York, pp. 211–241.

Singh-Joy, S.D. et al., (2008). Safety Assessment of Poloxamers 101, 105, 108, 122, 123,124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, Poloxamer 105 Benzoate, and Poloxamer 182 Dibenzoate as Used in Cosmetics. *International Journal of Toxicology*, **27**(Suppl. 2): 93–128.

### **Biophysical Studies on Poloxamer-188**

Guo, C., Liu, H., Wang, J. and Chen, J. (1999). Conformational structure of triblock copolymers by FT-Raman and FTIR spectroscopy. *J. Coll. Interface Sci.* **209**: 368-373.

Lee, R.C., Despa, F., Tang, X., Titushkin, I., and Cho, M. (2006). Direct observation of the p188 mediated membrane sealing with atomic force microscopy. *Mol. Cell. Biomech.* **3**: 185-186.

Maskarinec, S.A., Hannig, J., Lee, R.C. and Lee, K.Y. (2002). Direct observation of poloxamer 188 insertion into lipid monolayers. *Biophys. J.* **82**: 1453-1459.

Wu, G., Majewski, J., Ege, C., Kjaer, K., Weygand, M.J., and Lee, K.Y., (2004) Lipid corralling and Poloxamer squeeze-out in membranes. *Phys. Rev. Lett.* **93**:028101.

Wu, G., Majewski, J., Ege, C., Kjaer, K., Weygand, M.J., and Lee, K.Y., (2005). Interaction between lipid monolayers and Poloxamer 188: an X-ray reflectivity and defraction study. *Biophys. J.* **89**: 3159-73.

Wu, G., and Lee, K.Y.C. (2009). Interaction of poloxamers with liposomes: an isothermal titration calorimetry study. *J. Phys Chem.* **113**: 15522-15531.

Yang, J.-Y., Chin, J., Marks, J.D., and Lee, K.Y.C. (2010). Effects of PEO-PPO-PEO triblock copolymers on phospholipid membrane integrity under osmotic stress. *Langmuir* **26**: 12953-12961.



### **Poloxamer-188: Other Studies**

Borgens, R.B., Bohnert, D., Duerstock, B., Spomar, D., Lee, R.C. (2004) Subcutaneous tri-block copolymer produces recovery from spinal cord injury. *J Neurosci Res* **76**: 141-154.

Cadichon, S.B., Le, H.M., Wright, D.A., Curry, D.J., Kang, U., and Frim, D.M. (2007). Neuroprotective effect of the surfactant poloxamer 188 in a model of intracranial hemorrhage in rats. *J. Neurosurg* (1Suppl. Pediatrics) **106**: 36-40.

Carter, C., Fisher, T.C., Hamai, H., Johnson, C.S., Meiselman, H.J., Nash, G.B., and Stuart J. (1992) Haemorheological effects of a nonionic copolymer surfactant (poloxamer 188). *Clin. Hemorheol.* **12**: 109-120.

Cheung, A.T., Chan, M.S., Ramanujam, S., Rangaswami, A., Curl, K., Franklin, P., et al. (2004). Effects of Poloxamer 1888 treatment of sickle cell vaso-occlusive crisis: a computer-assisted intravital microscopic study. *J. Investig. Med.* **52**: 402-406.

Isaac, D.I., Golenberg, N., and Haut, R.C. (2010). Acute repair of chondrocytes in the rabbit tibiofemoral joint following blunt impact using P188 surfactant and a preliminary investigation of long term efficacy. *J. Orthop. Res.* **28**: 553-558.

Janoff, A.S., Mazorow, D.L., Coughlin, R.T., Bowdler, A.J., Haug, A., and McGroarty, E.J. (1981). The modification of human erythrocyte membrane structure by membrane stabilizers: an electron spin resonance study. *Am. J. Hematol.* **10**: 171-179.

Lechman, T., and Reinhart, W.H. (1998). The non-ionic surfactant Poloxamer 188 (RheothRx®) increases plasma and whole blood viscosity. *Clin. Hemorheol. Microcirc.* **18**: 31-36.

Moghimi, S.M. and Murray, J.C. (1996). Poloxamer-188 revisited: a potentially valuable immune modulator? *J. Natl. Cancer Inst.* **88**: 766-768.

Reeve, L. (1997). The poloxamers: their chemistry and medical applications. *In Handbook of Biodegradable Polymers*, Domb, A.J., Kost, J., and Wiseman, D.M. eds. Harwood Academic Publishers. Amsterdam. pp. 231-249.

Sarvottam, B., Shoemaker, T., Hakimiyan, A.A., Rappoport, L., Pascual-Garrido, C., Oegema, T.R., Wimmer, M.A., and Chubinskaya, S. (2010). Protective effect of P188 in the model of acute trauma to ankle cartilage: the mechanism of action. *J. Orthop. Trauma* **24**: 571-576.

Schaer, G.L., Hursey, T.L., Rodriguez, E.R., Campbell, D.R., Song, J.K., Manabat, N.C., et al. (1991) Poloxamer 188, a component of perfluorochemical emulsion (Fluosol), reduces myocardial infarct size in dogs [abstract]. *Circulation* **84**: II-619.

Smith, C.M., Hebbel, R.P., Tukey, D.P., Clawson, C.C., White, J.G., Vercellotti, G.M. (1987). Pluronic F68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. *Blood* **69**: 1631-1636.

### **Loss of Dystrophin in Non-genetic Models of Heart Failure.**

Andreoletti, L., Venteo, L., Douche-Aourik, F., Canas, F., de la Grandmaison, G.L., Jaques, J., et al., (2007). Active coxsackieviral B infection is associated with disruption of dystrophin in endomyocardial tissue of patients who died suddenly of acute myocardial infarction. *J. Am. Coll. Cardiol.* **50**: 2207-2214.

Kaprielian, R.R. and Severs, N.J. (2000) Dystrophin and the cardiomyocyte membrane cytoskeleton in the healthy and failing heart. *Heart Failure Reviews* **5**: 221-238.

Kawada, T., Masui, F., Kumagai, H., Koshimizu, M., Nakazawa, M., and Toyo-oka, T. (2005). A novel; paradigm for the therapeutic basis of advanced heart failure-assessment by gene therapy. *Pharmacol. Therap.* **107**: 31-43.

Kido, M., Otani, H., Kyoj, S., Sumida, T., Fujiwara, H., Okada, T., and Imamura, H., (2004). Ischemic preconditioning-mediated restoration of membrane dystrophin during reperfusion correlates with protection against contraction-induced myocardial injury. *Am. J. Heart Circ. Physiol.* **287**: H81-H90.

Kyoj, S., Otani, H., Hamano, A., Matsuhisa, S., Akita, Y., Fujiwara, H., Hattori, R., Imamura, H., Kamihata, H., Iwasaka, T. (2006). Dystrophin is a possible end-target of ischemic preconditioning against cardiomyocyte oncosis during the early phase of reperfusion. *Cardiovasc. Res.* **70**: 354-363.

Lee, G.H., Badorff, C., Knowlton, K.U. (2000). Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy. *Circ. Res.* **87**: 489-95.

Maybaum, S., Mancini, D., Xydas, S., Starling, R.C., Aaronson, K., Pagani, F.D., Miller, L.W., Margulies, K., McRee, S., Frazier, O.H., Torre-Amione, G. (2007). Cardiac improvement during mechanical circulatory support. A prospective multicenter study of the LVAD working group. *Circulation* **115**: 2497-2505.

Takahashi, M., Tanonaka, K., Yoshida, H., Koshimizu, M., Oikawa, R., Daicho, T., and Takeo, S. (2005a). Effects of angiotensin I-converting enzyme inhibitor and angiotensin II type 1 receptor blocker on the right ventricular sarcoglycans and dystrophin after left coronary artery ligation. *Eur. J. Pharmacol.* **522**: 84-93.

Takahashi, M., Tanonaka, K., Yoshida, H., Oikawa, R., Koshimizu, M., Daicho, T., Toyo-oka, T., and Takeo, S., (2005b). Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in heart failure. *Cardiovasc. Res.* **56**: 356-365.



Towbin, J.A. and Vatta, M. (2007) Myocardial infarction, viral infection, and the cytoskeleton: final common pathways to a common disease? *J. Am. Coll. Cardiol.* **50**: 2215-2217.

Toyo-Oka, T., Kawada, T., Nakata, J., Xie, H., Urabe, M., Masui, F., Ebisawa, T., Tezuka, A., Iwasawa, K., Nakajima, T., Uehara, Y., Kumagai, H., Kostin, S. Schaper, J., Nakazawa, M., and Ozawa, K. (2004). Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction. *Proc. Natl. Acad. Sci. U.S.A.* **101**: 7381-7385.

Vatta, M., Stetson, S.J., Jimenez, S., Entman, M.L., Noon, G.P., Bowles, N.E., Towbin, J.A., and Torre-Amione, G. (2004). Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. *J. Am. Col. Cardiol.* **43**: 811-817.

Vatta, M., Stetson, S.J., Perez-Verdia, A., Entman, M.L., Noon, G.P., Torre-Amione, G., Bowles, N.E., Towbin, J.A. (2002). Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. *Lancet* **359**: 936-941.

Wallace, C.K., Koerner, M.M., Thohan, V., Loebe, M., Lafuente, J., Noon, G.P., Torre-Amione, G. (2004). The response of the failing heart to chronic mechanical unloading. *Curr. Opin. Cardiol.* **19**: 270-277.

Yoshida, H., Takahashi, M., Koshimizu, M., Tanonaka, K., Oikawa, R., Toyo-oka, T., Takeo, S. (2003). Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction. *Cardiovasc Res.* **59**: 419-27.

### **Cardiomyopathy in Muscular Dystrophy.**

American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. (2005). Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. *Pediatrics* **116**: 1569-1573.

Chetboul, V., Carlos, C., Blot, S., Thibaud, J.L., Escriou, C., Tissier, R., Retortillo, J.L., and Pouchelon, J.L. (2004). Tissue Doppler assessment of diastolic and systolic alterations of radial and longitudinal left ventricular motions in Golden Retrievers during the preclinical phase of cardiomyopathy associated with muscular dystrophy. *Am. J. Vet. Res.* **65**:1335-1341.

Duboc, D., Meune, C., Lerebours, G., Devaux, J.Y., Vaksman, G., Bécane, and H.M. (2005). Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. *J. Am. Coll. Cardiol.* **45**: 855-857.

Duboc, D., Meune, C., Pierre, B., Wahbi, K., Eymard, B., Toutain, A., Berard, C., Vaksman, G., Weber, S., Bécane, H.M. (2007). Perindopril preventive treatment on



mortality in Duchenne muscular dystrophy: 10 years' follow-up. *Am. Heart J.* **154**: 596-602.

Emery, A.E. (2002). The muscular dystrophies. *Lancet* **359**: 687-695.

Finsterer, J. and Stollberger, C. (2003). The heart in human dystrophinopathies. *Cardiology* **99**: 1-19.

Goodwin, F.C., and Muntoni, F. (2005). Cardiac involvement in muscular dystrophies: molecular mechanisms. *Muscle Nerve* **32**: 577-588.

Kajimoto, H., Ishigaki, K., Okumura, K., Tomimatsu, H., Nakazawa, M., Saito, K., Osawa, M., and Nakanishi, T. (2006). Beta blocker therapy for cardiac dysfunction in patients with muscular dystrophy. *Circ. J.* **70**: 991-994

Khairallah, M., Khairallah, R., Young, M.E., Dyck, J.R., Petrof, B.J. and Des Rosiers, C. (2007). Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. *J. Mol. Cell. Cardiol.* **43**: 119-129.

Markham, L.W., Kinnett, K., Wong, B.L., Benson, W.D., and Cripe, L.H. (2009). Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. *Neuromuscul. Disord.* **18**: 365-370.

McNally, E.M. (2007). New approaches in the therapy of cardiomyopathy in muscular dystrophy. *Annu. Rev. Med.* **58**: 75-88.

Nigro, G., Comi, L.I., Politano, L., and Bain, R.J. (1990). The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. *Int. J. Cardiol.* **26**: 271-277.

Ogata, H., Ishikawa, Y., Ishikawa, Y., and Minami, R. (2009). Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. *J. Cardiol.* **53**: 72-78.

Puchalski, M.D., Williams, R.V., Askovich, B., Sower, C.T., Hor, K.H., Su, J.T., Pack, N., Dibella, E., and Gottliebson, W.M. (2009). Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? *Int. J. Cardiovasc. Imaging* **25**: 57-63.

Rhodes, J., Margossian, R., Darras, B.T., Colan, S.D., Jenkins, K.J., Geva, T., Powell, A.J. (2008). Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. *Pediatr. Cardiol.* **29**: 343-351.

Saito, T., Matsumura, T., Miyai, I., Nozaki, S., and Shinno, S. (2001). [Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy]. *Rinsho Shinkeigaku* **41**: 691-694.

Towbin, J.A., Hejtmancik, J.F., Brink, P., Gelb, B., Zhu, X.M., Chamberlain, J.S., McCabe, E.R., and Swift, M. (1993) X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. *Circulation* **87**:1854-1865.

Townsend, D., Yasuda, S., Li, S., Chamberlain, J.S., Metzger, J.M. (2008). Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. *Mol. Ther.* **16**: 832-835.

Valentine, B.A., Cummings, J.F., and Cooper, B.J. (1989). Development of Duchenne-type cardiomyopathy. Morphologic studies in a canine model. *Am. J. Pathol.* **135**: 671-678.

### **Contraction-Induced Injury in Muscular Dystrophy.**

Consolino, C.M., and Brooks, S.V. (2004) Susceptibility to sarcomere injury induced by single stretches of maximally activated muscles of mdx mice. *J. Appl. Physiol.* **96**: 633-638.

Danielou, G., Comtois, A.S., Dudley, R., Karpati, G., Vincent, G., Des Rosiers, C., Petrof, B.J. (2001). Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. *FASEB J.* **15**: 1655-7.

Doherty, K.R., and McNally, E.M. (2003). Repairing the tears: dysferlin in muscle membrane repair. *Trends Mol. Med.* **9**: 327-330.

Emery, A.E. (2002). The muscular dystrophies. *Lancet* **359**: 687-695.

Ervasti, J.M. and Campbell, K.P. (1993a). Dystrophin and the membrane skeleton. *Curr. Opin. Cell Biol.* **5**: 82-87.

Ervasti, J.M. and Campbell, K.P. (1993b). Dystrophin-associated glycoproteins: their possible roles in the pathogenesis of Duchenne muscular dystrophy. *Mol. Cell Biol. Hum. Dis. Ser.* **3**: 139-166.

Han, R., Bansal, D., Miyake, K., Muniz, V.P., Weiss, R.M., McNeil, P.L., Campbell, K.P. (2007) Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. *J. Clin. Invest.* **117**: 1805-1813.

Ho, M., Post, C.M., Donahue, L.R., Lidov, H.G.W., Bronson, R.T., Goolsby, H., Watkins, S.C., Cox, G.A. and Brown, R.H. (2004). Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. *Hum. Mol. Genet.* **13**: 1999-2010.



Lynch, G.S. (2004). Role of contraction-induced injury in the mechanisms of muscle damage in muscular dystrophy. *Clin. Expt. Pharmacol Physiol.* **31**: 557-561.

Marques, M.J., Ventura Machado, R., Minatel, E., Santo Neto, H. (2008) Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness. *Muscle Nerve* **37**: 61-67.

Schertzer, J.D., Ryall, J.G., Lynch, G.S. (2006). Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice. *Am. J. Physiol. Endocrinol. Metab.* **291**: E499-505.

Straub, V., Rafael, J., Chamberlain, J.S. and Campbell, K.P. (1997). Animal models for muscular dystrophy show different patterns of sarcolemma disruption. *J. Cell. Biol.* **139**: 375-385.